Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
Saved in:
| Title: | Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. |
|---|---|
| Authors: | Armstrong, A.1, Bui, C.2, Fitch, K.3, Sawhney, T. Goss3, Brown, B.2, Flanders, S.2, Balk, M.4, Deangelis, J.2, Chambers, J.5 |
| Source: | Current Medical Research & Opinion. Jun2017, Vol. 33 Issue 6, p1133-1139. 7p. |
| Database: | Academic Search Ultimate |
| ISSN: | 03007995 |
|---|---|
| DOI: | 10.1080/03007995.2017.1308919 |
